关键词: font-size:13.3333px, ">乌司他丁；早期脓毒症；28 d病死率；ICU住院时间

Abstract: Objective： To investigate the clinical efficacy of ulinastatin for patients with early sepsis. Methods： Totally 158 cases of early sepsis patients diagnosed and treated in our hospital from January 2020 to December 2020 were enrolled and equally randomized into experimental group (n=79) and control group (n=79). The control group was treated with traditional treatment， while the experimental group additionally received ulinastatin on the basis of traditional treatment. The differences of intensive care unit (ICU) hospitalization length， mortality， symptom improvement and other indicators between the two groups were observed. Results： Considerably outstanding results were observed in favor of experimental group as compared to the control group with respect to 28-day mortality (8.86% vs 18.98%) and complications (11.39% vs 26.58%). Moreover， the experimental group yielded strikingly lower mlondialdehyde， serum superoxide dismutase (SOD)， procalcitonin(PCT) and sepsis-related organ fai lureassessment (SOFA) score than the control group； additionally， the control group spent drastically longer time of norepinephrine， epinephrine， antibiotics and ICU stay in contrast to the experimental group； serum creatinine (SCR)， brain natriuretic peptide (BNP)， creatine kinase-MB (CK-MB) and Hydrobutyric dehydrogenase (HBDH) in the experimental group were remarkably lower than those in the control group (P＜0.05). Conclusion： Additional use of ulinastatin on the basis of traditional treatment may be a boon for patients with early sepsis due to its numerous benefits in terms of lowering the mortality and the incidence of complications， shortening the medication time and prognosis time， and excellent prognosis，providing references for clinical medication.

Key words: font-size:13.3333px, ">Ulinastatin； Early sepsis； 28-day mortality； Length of stay in ICU